Won't be long now...By the end of this month, we should have more solid data indicating the success rates for our lead PDC, TLD-1433 in fighting Non-Muscle Invasive Bladder Cancer from our Phase 2 study.
Will it be enough to move us to pursue Breakthrough Designation with the FDA?
I believe it will.
We have Fast Track, we have a Phase 1 that was wrapped up early due to overwhelming success...
And that proof of TLD-1433's non-toxicity and high tolerability may be what we need to bring our CURE FOR CANCER to market soon...
Because, remember, this Phase 2 study allows for only two treatments per patient, which may vary in success due to correctness of application.
In real life, patients can repeat treatment 2, 3, or more times until success is achieved...
That means a very possible 100% success rate!
And the added benefit of possible immunity to cancer for treated patients... well, that's the icing on a very delicious cake!
The days are growing longer, and the time is moving so slowly until the results are in...
But it's worth the wait, hehehe.
Good Luck To All TLT investors!
(P.S. Don't even talk to me about cheapo takeover bids. If this truly IS the cure for cancer, look at companies like Apple and Amazon for guidance on share prices of the future... And hold on to yours if you've got 'em!)